<div id="readability-page-1"><p>Janus Henderson Group PLC boosted its holdings in shares of  Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 32.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 476,023 shares of the biopharmaceutical company's stock after buying an additional 115,832 shares during the quarter. Janus Henderson Group PLC owned 0.40% of Catalyst Pharmaceuticals worth $9,935,000 at the end of the most recent reporting period.</p><ul><li>2 Biotechs Making Waves With A Single Product in their Pipeline</li></ul><p>A number of other institutional investors also recently bought and sold shares of CPRX. Farther Finance Advisors LLC grew its stake in shares of  Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares during the period.  Allspring Global Investments Holdings LLC grew its stake in  Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after acquiring an additional 50,888 shares during the period.  Spire Wealth Management boosted its stake in  Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 13,429 shares during the last quarter.  Sanctuary Advisors LLC boosted its stake in  Catalyst Pharmaceuticals by 91.5% during the 4th quarter. Sanctuary Advisors LLC now owns 59,447 shares of the biopharmaceutical company's stock worth $1,241,000 after purchasing an additional 28,407 shares during the last quarter.  Finally, Nilsine Partners LLC acquired a new stake in  Catalyst Pharmaceuticals during the 4th quarter worth $700,000. 79.22% of the stock is owned by hedge funds and other institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>Several brokerages have recently weighed in on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Friday, February 28th. HC Wainwright  reissued a &#34;buy&#34; rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Stephens  reissued an &#34;overweight&#34; rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Monday, February 3rd. Finally, Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of &#34;Buy&#34; and an average target price of $32.29.</p><ul><li>Small-Cap Catalyst Pharma Is Among Market's Best Price Performers</li></ul><p><b>View Our Latest Analysis on CPRX</b></p><h2>Catalyst Pharmaceuticals Price Performance</h2><p>Catalyst Pharmaceuticals stock opened at $24.37 on Friday. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.75 and a 12 month high of $26.16. The business has a 50 day simple moving average of $23.23 and a 200-day simple moving average of $22.47. The stock has a market capitalization of $2.97 billion, a PE ratio of 20.65, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. </p><h2>Insider Transactions at Catalyst Pharmaceuticals</h2><p>In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares of the company's stock, valued at $4,333,200.72. The trade was a 25.04% decrease in their position. The disclosure for this sale can be found here. Insiders sold 351,879 shares of company stock worth $8,214,815 over the last 90 days. 10.40% of the stock is currently owned by insiders. </p><h2>Catalyst Pharmaceuticals Company Profile</h2> (Free Report)<p>Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Catalyst Pharmaceuticals</li><li>How to Calculate Inflation Rate</li><li>Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision</li><li>How to Effectively Use the MarketBeat Ratings Screener</li><li>Retail Investors Are Betting Big on Rocket Lab—Should You Too?</li><li>Where Do I Find 52-Week Highs and Lows?</li><li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1BSWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Catalyst Pharmaceuticals Right Now?</h2><p>Before you consider Catalyst Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.</p><p>While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CPRX

<p>Janus Henderson Group PLC increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 32.2% in Q4, owning 476,023 shares valued at approximately $9.9 million. Other institutional investors also raised their stakes. Analysts have given Catalyst Pharmaceuticals a consensus rating of "Buy" with an average target price of $32.29. The stock opened at $24.37, with a 12-month range of $14.75 to $26.16. Recent insider transactions included significant share sales by executives.</p>

Janus Henderson Group PLC Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)